{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:23:03Z","timestamp":1780348983665,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":2412,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.bbmt.2008.04.012","type":"journal-article","created":{"date-parts":[[2008,6,4]],"date-time":"2008-06-04T05:02:58Z","timestamp":1212555778000},"page":"949-958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Allogeneic Hematopoietic Cell Transplantation for Adult Philadelphia-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"14","author":[{"given":"Yasser R.","family":"Abou Mourad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo F.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2008.04.012_bib1","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2008.04.012_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1040-8428(00)00097-4","article-title":"Recent approaches in acute lymphoblastic leukemia in adults","volume":"36","author":"Hoelzer","year":"2000","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bbmt.2008.04.012_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0889-8588(05)70198-2","article-title":"Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"15","author":"Radich","year":"2001","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.bbmt.2008.04.012_bib5","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/sj.leu.2402289","article-title":"Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period","volume":"15","author":"Thomas","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.04.012_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.bmt.1703899","article-title":"Bone marrow transplant in Ph+ ALL patients","volume":"31","author":"Avivi","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.04.012_bib7","first-page":"856a","article-title":"Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph +) acute lymphoblastic leukemia (ALL). Results from the international ALL trial (MRC UKALLXII\/ECOG E2993)","volume":"98","author":"Goldstone","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib8","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1182\/blood.V85.11.3353.bloodjournal85113353","article-title":"Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"85","author":"Chao","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib9","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014results of the prospective multicenter LALA-94 trial","volume":"100","author":"Dombret","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib10","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1038\/sj.leu.2401589","article-title":"Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission","volume":"13","author":"Snyder","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.04.012_bib11","first-page":"663","article-title":"Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia","volume":"16","author":"Stockschl\u00e4der","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.04.012_bib12","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1182\/blood.V79.11.3067.3067","article-title":"Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"79","author":"Barrett","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib13","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V90.4.1410","article-title":"Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"90","author":"Sierra","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.2003.03988.x","article-title":"Risk factors for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction","volume":"120","author":"Lee","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2008.04.012_bib15","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2008.04.012_bib16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1126\/science.3422516","article-title":"Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL)","volume":"239","author":"Clark","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2008.04.012_bib17","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","article-title":"Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia","volume":"91","author":"Faderl","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib18","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2008.04.012_bib20","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib21","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/sj.leu.2403062","article-title":"Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment","volume":"17","author":"Scheuring","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.04.012_bib22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.leu.2402808","article-title":"Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias","volume":"17","author":"Shimoni","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.04.012_bib23","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/sj.leu.2402770","article-title":"Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)","volume":"16","author":"Wassmann","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.04.012_bib24","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib25","first-page":"10a","article-title":"Long-term follow-up after frontline therapy with hyper-CVAD and imatinib mesylate regimen in adults with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL)","volume":"110","author":"Thomas","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib26","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","article-title":"Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia","volume":"104","author":"Towatari","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib27","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood-2004-09-3785","article-title":"The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"105","author":"Lee","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib28","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","article-title":"Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study","volume":"109","author":"de Labarthe","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib29","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib30","doi-asserted-by":"crossref","first-page":"10a","DOI":"10.1182\/blood.V110.11.8.8","article-title":"Does imatinib change the outcome in Philapdelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII\/ECOG2993 study","volume":"110","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib31","first-page":"79","article-title":"Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adults","volume":"15","author":"Martin","year":"2001","journal-title":"Hematol Oncol Clinic North Am"},{"key":"10.1016\/j.bbmt.2008.04.012_bib32","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2003-01-0154","article-title":"Early prediction of response in patients with relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib","volume":"103","author":"Wassmann","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib33","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.04.012_bib34","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","article-title":"Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"106","author":"Wassmann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib36","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1182\/blood.V89.7.2602","article-title":"Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation","volume":"89","author":"Radich","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib37","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2008.04.012_bib38","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2008.04.012_bib39","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bbmt.2008.04.012_bib40","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","author":"Brave","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2008.04.012_bib41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2008.04.012_bib42","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib43","doi-asserted-by":"crossref","first-page":"826a","DOI":"10.1182\/blood.V110.11.2810.2810","article-title":"Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015)","volume":"110","author":"Porkka","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib44","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"10.1016\/j.bbmt.2008.04.012_bib45","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.3816\/CLM.2007.s.006","article-title":"Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia","author":"Mughal","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.bbmt.2008.04.012_bib46","doi-asserted-by":"crossref","first-page":"828a","DOI":"10.1182\/blood.V110.11.2814.2814","article-title":"Phase II study of combination of the hyper-CVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or BCR-ABL positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB)","volume":"110","author":"Ravandi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib47","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2008.04.012_bib48","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/cncr.21299","article-title":"AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells","volume":"104","author":"Verstovsek","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2008.04.012_bib49","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.04.012_bib50","first-page":"828a","article-title":"Nilotinib in patients (pts) with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib51","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/asheducation-2005.1.118","article-title":"Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia","author":"Ottmann","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2008.04.012_bib52","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/cncr.22631","article-title":"Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)","volume":"109","author":"Ottmann","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2008.04.012_bib53","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.leu.2404320","article-title":"Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study","volume":"20","author":"Delannoy","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.04.012_bib54","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.leukres.2005.04.020","article-title":"Treatment of elderly patients with acute lymphoblastic leukemia\u2014evidence for a benefit of imatinib in BCR-ABL positive patients","volume":"29","author":"Brandwein","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2008.04.012_bib55","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"Vignetti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib56","doi-asserted-by":"crossref","first-page":"10a","DOI":"10.1182\/blood.V110.11.7.7","article-title":"Dasatinib as front-line monotherapy for the induction treatment of adult and elderly Ph+ acute lymphoblastic leukemia (ALL) patients: interim analysis of the GIMEMA prospective study LAL1205","volume":"110","author":"Foa","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.04.012_bib57","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879108001778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879108001778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:32:12Z","timestamp":1761057132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879108001778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S1083879108001778"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2008.04.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Hematopoietic Cell Transplantation for Adult Philadelphia-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2008.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}